Yes, Sanofi US Services (formerly Sanofi-Aventis US) is "just" a subsidiary, but it's still one of the largest pharmaceutical companies in the country. As the US operations of global drugmaker Sanofi, the company develops, manufactures, and markets pharmaceutical products for a range of ailments. Its principal therapeutic areas include cardiovascular disease, central nervous system ailments, internal medicine, metabolic disorders, oncology, and ophthalmology. Some of its key products include injectable insulin Lantus, cancer drug Taxotere, thrombosis treatment Lovenox, and blood thinner Plavix. Sanofi US Services markets its parent's products in the US through its thousands of field sales professionals.
Sanofi US Services also operates four research centers in Arizona, Massachusetts, New Jersey, and Pennsylvania, a production plant and a packaging facility (both in Missouri), a US distribution center in Georgia.
The production facility in Kansas City, Missouri, is one of Sanofi's primary manufacturing sites, producing pharmaceuticals for both US an global markets. In addition, its facility in St. Louis, Missouri, offers contract pharmaceutical packaging for other manufacturers. Its services include filling of capsules, gel caps, or tablets in various sizes and shapes, including glass and plastic.
The company’s pharmaceutical products include Apidra (insulin glulisine injection), Eloxatin (oxaliplatin injection), Lantus (insulin glargine injection), Jevtana (cabazitaxel) Injection, and Taxotere (docetaxel) Injection Concentrate.
Sanofi US Services is a part of pharmaceutical segment of its parent company. In 2014 the segment accounted for 82% of Sanofi's revenues; the US, 34%.
Sanofi US Services handles the pharmaceuticals business of France-based parent Sanofi in the US market. It works alongside the US location of Sanofi's vaccines business, sister company Sanofi Pasteur Inc., and Sanofi's global animal health business, Merial, which is headquartered in the US.
The firm's R&D functions are increasingly important to global Sanofi operations as the drugmaker works to product new blockbuster drugs to replace those going off-patent, such as Plavix (co-marketed with Bristol-Myers Squibb).
In 2014, ZAI Lab Limited entered into a global licensing agreement with the company for two novel compounds potential treatment of chronic respiratory diseases including chronic obstructive pulmonary disease, asthma and idiopathic pulmonary fibrosis. ZAI Lab will be responsible for global development, manufacturing, and commercialization of the two clinical ready novel programs. Sanofi US Services will potentially receive development and regulatory approval milestones and tiered royalties from the global net sales of the licensed products.
In 2011 parent Sanofi established an even deeper footprint in the US market through the $20 billion acquisition of biotech firm Genzyme. Another sister company, US-based consumer health products maker Chattem, was added in late 2009. Genzyme and Chattem represent the main biotechnology and consumer health subsidiaries of the Sanofi organization.